Acumen Pharmaceuticals Inc Aktie News

NEWTON, Mass., 10. Sept. 2026 (GLOBE NEWSWIRE) – Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) („Acumen“ oder das „Unternehmen“), ein biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige Therapeutika entwickelt, die toxische lösliche Amyloid‑Beta-Oligomere zur Behandlung der Alzheimer‑Krankheit anvisieren, gab heute bekannt, dass das Unternehmen am Mittwoch, den 16. Sept. 2026 um ...

NEWTON, Mass., 12. Aug. 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) ("Acumen" oder das "Unternehmen"), ein im klinischen Stadium befindliches Biopharmaunternehmen, das neuartige Therapeutika entwickelt, die toxische lösliche Amyloid‑beta‑Oligomere (AβOs) zur Behandlung der Alzheimer‑Krankheit (AD) anvisieren, berichtete heute die Finanzergebnisse für das zweite Quartal ...

NEWTON, Mass., 15. Juli 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), ein biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige Therapeutika entwickelt, die lösliche Amyloid‑Beta‑Oligomere (AβOs) für die Behandlung der Alzheimer‑Krankheit (AD) anvisieren, gab heute neue Ergebnisse bekannt, die auf der Alzheimer's Association International Conferen...

HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) exercised its exclusive option to develop, manufacture, and commercialize, on a global basis, up to two candidates for development in the treatm...

ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR Pharmaceuticals EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic Acumen's EBD candidates are designed to achieve higher brain penetrati...

Acumen Pharmaceuticals NASDAQ: ABOS said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer's disease pipeline.

NEWTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the first quarter of 2026 and provided a business update.